Colonial River Wealth Management LLC Has $504,000 Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Colonial River Wealth Management LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 33.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,751 shares of the medical research company’s stock after buying an additional 441 shares during the period. Colonial River Wealth Management LLC’s holdings in Amgen were worth $504,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. OFI Invest Asset Management acquired a new position in shares of Amgen during the 3rd quarter worth about $26,000. Briaud Financial Planning Inc bought a new stake in shares of Amgen in the 3rd quarter valued at about $26,000. VisionPoint Advisory Group LLC bought a new stake in shares of Amgen in the 2nd quarter valued at about $28,000. Strategic Investment Solutions Inc. IL bought a new stake in shares of Amgen in the 1st quarter valued at about $28,000. Finally, Providence Capital Advisors LLC bought a new stake in shares of Amgen in the 3rd quarter valued at about $30,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

NASDAQ:AMGN traded down $6.83 during midday trading on Tuesday, hitting $276.21. The company had a trading volume of 2,220,460 shares, compared to its average volume of 3,009,285. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72. The stock’s fifty day moving average price is $288.67 and its 200-day moving average price is $281.34. The company has a market capitalization of $148.03 billion, a PE ratio of 22.38, a P/E/G ratio of 2.69 and a beta of 0.58. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14.

Amgen (NASDAQ:AMGNGet Free Report) last announced its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. During the same period in the previous year, the business earned $4.09 earnings per share. The firm’s quarterly revenue was up 19.8% compared to the same quarter last year. As a group, research analysts expect that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.26%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is presently 72.06%.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of research analyst reports. StockNews.com cut shares of Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Raymond James started coverage on shares of Amgen in a research report on Thursday, March 28th. They set a “market perform” rating on the stock. Morgan Stanley cut their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 7th. Oppenheimer reaffirmed an “outperform” rating and issued a $350.00 price target on shares of Amgen in a research report on Thursday, February 1st. Finally, UBS Group dropped their target price on shares of Amgen from $315.00 to $314.00 and set a “neutral” rating on the stock in a research report on Monday, January 29th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $295.30.

Get Our Latest Research Report on Amgen

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.